- Home
- NAAS vs FGEN Comparison
NAAS vs FGEN Comparison
Compare NAAS & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- FGEN
- Stock Information
- Founded
- NAAS 2019
- FGEN 1993
- Country
- NAAS China
- FGEN United States
- Employees
- NAAS N/A
- FGEN N/A
- Industry
- NAAS Other Specialty Stores
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- NAAS Consumer Discretionary
- FGEN Health Care
- Exchange
- NAAS Nasdaq
- FGEN Nasdaq
- Market Cap
- NAAS 40.1M
- FGEN 34.0M
- IPO Year
- NAAS 2017
- FGEN 2014
- Fundamental
- Price
- NAAS $2.91
- FGEN $0.33
- Analyst Decision
- NAAS
- FGEN
- Analyst Count
- NAAS 0
- FGEN 0
- Target Price
- NAAS N/A
- FGEN N/A
- AVG Volume (30 Days)
- NAAS 141.1K
- FGEN 1.6M
- Earning Date
- NAAS 11-20-2024
- FGEN 11-12-2024
- Dividend Yield
- NAAS N/A
- FGEN N/A
- EPS Growth
- NAAS N/A
- FGEN N/A
- EPS
- NAAS N/A
- FGEN N/A
- Revenue
- NAAS $58,241,066.00
- FGEN $180,015,000.00
- Revenue This Year
- NAAS $19.53
- FGEN $20.42
- Revenue Next Year
- NAAS $151.36
- FGEN N/A
- P/E Ratio
- NAAS N/A
- FGEN N/A
- Revenue Growth
- NAAS 199.95
- FGEN 16.15
- 52 Week Low
- NAAS $1.42
- FGEN $0.18
- 52 Week High
- NAAS $59.20
- FGEN $2.93
- Technical
- Relative Strength Index (RSI)
- NAAS 45.72
- FGEN 48.26
- Support Level
- NAAS $2.50
- FGEN $0.18
- Resistance Level
- NAAS $2.95
- FGEN $0.43
- Average True Range (ATR)
- NAAS 0.22
- FGEN 0.05
- MACD
- NAAS 0.01
- FGEN 0.01
- Stochastic Oscillator
- NAAS 56.10
- FGEN 63.14
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.